New NGS Workflow Cuts Reagent Costs by Over 70 Percent
The platform automates library preparation for clinical diagnostics, reducing manual labor to under five minutes per run.
Updated on Oct. 21, 2026 in Life Sciences
Live Poll
Do you believe automated lab testing improves the efficiency of clinical diagnostics in your area?
CyteSi has validated a next-generation sequencing library preparation workflow on the Turing Biosystem D1 platform using QIAGEN kits. This announced development aims to standardize sample preparation and reduce operational costs in clinical diagnostic environments.
Why it matters
The validation addresses critical industry demands for cost control and reproducibility in clinical diagnostics. By digitizing liquid handling, the workflow seeks to bridge the gap between high-throughput sequencing needs and the operational constraints of clinical labs.
The Turing Biosystem D1 platform processes up to 6 samples per run with less than 5 minutes of hands-on time, representing a 70% reduction in reagent costs compared to established manual library preparation workflows.
The players
CyteSi
A Menlo Park-based company focused on developing automated library preparation workflows for genomic sequencing.
Intelligent Biosystems
A provider of industrial-scale biological data-generation capabilities that conducted the platform validation in Hangzhou.
QIAGEN
A global provider of sample and assay technologies for molecular diagnostics and life science research.
The details
The D1 platform functions by miniaturizing and digitizing liquid-handling steps, which are the physical movements of fluid samples necessary for genomic analysis. Intelligent Biosystems utilized their industrial-scale biological data-generation infrastructure to execute the validation, ensuring the workflow integrates seamlessly with existing standardized sequencing kits.
Timeline
October 21, 2026: CyteSi announced the successful validation of the NGS workflow.
The Tech Race
This workflow validation places the Turing Biosystem D1 platform in direct competition with established automated liquid-handling systems for genomic library preparation. It represents a significant step in the industry-wide effort to reduce labor costs and increase standardization in clinical diagnostics.
Clinical diagnostic laboratories can expect potential cost efficiencies if the D1 platform is integrated into their existing NGS pipelines. Availability of the validated workflow will depend on future kit compatibility support as planned by CyteSi and QIAGEN.
The takeaway
The industry is moving toward fully automated, high-reproducibility workflows to meet the rising demand for clinical sequencing. Professionals should monitor upcoming announcements from CyteSi regarding the expanded compatibility of standardized kits with the Turing Biosystem D1.
Further reading
For broader developments in genomic technologies, explore the Life Sciences section.
Source note: This article includes information reported by ELE Times.
Live Poll
Do you believe automated lab testing improves the efficiency of clinical diagnostics in your area?
